Pulmonary Hypertension Clinical Trial
Official title:
Noninvasive Diagnosis of Pulmonary Hypertension Using Three-dimensional Interventricular Septal Curvedness From Cardiac Magnetic Resonance Images
In this study, study team aim to i) evaluate the accuracy of 3D IVS curvedness for prediction of RV systolic pressure (RVSP), mean pulmonary artery pressure (mPAP) and pulmonary vascular resistance (PVR) with RHC; ii) evaluate the usefulness of 3D IVS curvedness for predicting the response to vasodilator challenge with RHC, in patients clinically suspected or known to have primary PH.
1) Pulmonary hypertension Pulmonary hypertension (PH) is manifested as an increase in mean
pulmonary artery pressure (i.e., mPAP ≥ 25 mmHg) at rest on right heart catheterization (RHC)
(Badesch 2009). It is a complex and multidisciplinary disorder causing restricted flow
through the pulmonary arterial circulation due to increased pulmonary vascular resistance
(PVR). It can be classified into five groups (Simonneau et al 2004): Group I - Idiopathic
PAH, Familial PAH, and PAH associated with collagen vascular disease et al; Group II - PH
with left heart disease; Group III - PH associated with lung diseases and/or hypoxemia; Group
IV - PH due to chronic thrombotic and/or embolic disease; and Group V - miscellaneous causes
of PH. The prognosis of PH is poor. The National Institutes of Health (NIH) Registry followed
194 patients with IPAH enrolled at 32 clinical centers from 1981 to 1985 (D'Alonzo et al
1991). The reported median survival rates of 68%, 48% and 34%. Similar results have been
reported in Japan, India and Mexico.
Right heart catheterization (RHC) is the current reference standard for diagnosing PH (Galie
et al 2009; McLaughlin et al 2009), according to ACCF/AHA expert consensus (McLaughlin et al
2009) and ESC/ERS guidelines (Galie et al 2009). Three hemodynamic measurements are essential
from RHC: right ventricular systolic pressure (RVSP), mean pulmonary artery pressure (mPAP)
and pulmonary vascular resistance (PVR). Further, patients with PH undergo RHC to assess
clinical response to vasodilator challenge in order to guide therapy. It helps identify
patients with better prognosis and patients who could potentially benefit from treatment with
calcium channel blockers. A positive acute response is defined as a reduction of pulmonary
artery pressure ≥10mmHg and ≤40mmHg. Although RHC plays a pivotal role in PH diagnosis, it is
invasive and not without its own inherent risks (Hoeper et al 2006). For these reasons,
development of a noninvasive alternative to RHC for diagnosis of PH is paramount.
Noninvasive diagnosis of PH and prediction of response to vasodilator challenge is clinically
needed.
Several noninvasive methods for diagnosis of PH have been propounded, the most common being
Doppler echocardiography. While routinely used to estimate pulmonary arterial pressure,
Doppler measurement of tricuspid regurgitation jet peak velocity has inherent limitations:
(i) the reliance on the visualization of the tricuspid regurgitant jet which is not always
detectable, (ii) the fact that peak velocity of the jet may be difficult to measure in the
presence of severe tricuspid regurgitation, and (iii) the need for adequate acoustic windows
(Hinderliter et al 2003; Hachulla et al 2005). Furthermore, as recently emphasized in the
ERS/ESC guideline (Galie et al 2009), estimation of mPAP or PVR must be an integral part of a
complete cardiac echocardiographic examination.
It has long been recognized that systolic flattening and abnormal motion of the
inter-ventricular septum (IVS), from either echocardiography (King et al 1983; Reisner et al
1994; Ricciardi et al 1999) or cine CMR images (Roeleveld et al 2005; Dellegrottaglie et al
2007; Alunni et al 2010), are signs of increased pulmonary arterial pressures. However, these
studies are either qualitative or limited to 2D assessment, relying for analysis on
subjective selection of the imaging plane and cardiac cycle phase. In the last 10 years,
despite advances in biomedical engineering and computational approaches, no rigorous studies
have been undertaken to study the relationship between quantitative 3D IVS shape and PH.
It is well documented that RV dysfunction and the 6-min walk test (6MWT) are associated with
increased risk of mortality in PH (van Wolfersen 2007). Study team has recently developed a
new method for assessment of RV function in terms of area strain, integrating radial,
circumferential and longitudinal deformation (Zhong et al 2012). Therefore, we will also
investigate the relationship between RV area strain and exercise capacity in PH.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT01950585 -
Hydroxyurea in Pulmonary Arterial Hypertension
|
Early Phase 1 | |
Completed |
NCT00527163 -
Role of Nitric Oxide in Malaria
|
||
Completed |
NCT03649932 -
Enteral L Citrulline Supplementation in Preterm Infants - Safety, Efficacy and Dosing
|
Phase 1 | |
Recruiting |
NCT04554160 -
Arrhythmias in Pulmonary Hypertension Assessed by Continuous Long-term Cardiac Monitoring
|
||
Enrolling by invitation |
NCT03683186 -
A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
|
Phase 3 | |
Completed |
NCT01894035 -
Non-interventional Multi-center Study on Patients Under Routine Treatment of Pulmonary Arterial Hypertension (PAH) With Inhaled Iloprost Using I-Neb as a Device for Inhalation
|
||
Not yet recruiting |
NCT04083729 -
Persistent Pulmonary Hypertension After Percutaneous Mitral Commissurotomy
|
N/A | |
Terminated |
NCT02243111 -
Detecting Pulmonary Arterial Hypertension (PAH) in Patients With Systemic Sclerosis (SSc) by Ultrasound
|
N/A | |
Completed |
NCT02216279 -
Phase-II Study of the Use of PulmoBind for Molecular Imaging of Pulmonary Hypertension
|
Phase 2 | |
Completed |
NCT02821156 -
Study on the Use of Inhaled NO (iNO)
|
N/A | |
Terminated |
NCT02246348 -
Evaluating Lung Doppler Signals in Patients With Systemic Sclerosis (SSc)
|
N/A | |
Recruiting |
NCT01913847 -
Safety and Efficacy Study of HGP1207 in Patients With Pulmonary Hypertension
|
Phase 3 | |
Completed |
NCT06240871 -
Contrast Enhanced PA Pressure Measurements
|
||
Completed |
NCT01615484 -
Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability
|
N/A | |
Completed |
NCT02377934 -
Evaluation of Radiation Induced Pulmonary Hypertension Using MRI in Stage III NSCLC Patients Treated With Chemoradiotherapy. A Pilot Study
|
||
Recruiting |
NCT01091012 -
Effectiveness of the Vasodilator Test With Revatio, Made in Patients With Acute Pulmonary Hypertension
|
Phase 3 | |
Completed |
NCT02275793 -
The Regulation of Pulmonary Vascular Resistance in Patients With Heart Failure
|
||
Completed |
NCT00739375 -
The Effect of Blood Flow in the Maturing Arteriovenous Access for Hemodialysis on the Development of Pulmonary Hypertension.
|
Phase 1 | |
Completed |
NCT01463514 -
Noninvasive Determination of Cerebral Tissue Oxygenation in Pulmonary Hypertension
|
N/A | |
Completed |
NCT01484899 -
Smoking: a Risk Factor for Pulmonary Arterial Hypertension?
|
N/A |